| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
550,600,000 as of 6/30 |
| Market
Cap: |
39.03(B) |
| Last
Volume: |
1,853,604 |
Avg
Vol: |
3,426,214 |
| 52
Week Range: |
$49.3 - $72.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 49 |
| Guru Rank Value : 10.9 |
| Guru Occurances : 4 |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile Baxter International develops, manufactures and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. Co. operates in the following segments: BioScience, which processes recombinant and plasma-based proteins; and Medical Products, which manufactures intravenous solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
155,800 |
209,050 |
341,600 |
1,175,240 |
| Total Sell Value |
$11,390,740 |
$15,004,900 |
$22,974,565 |
$70,121,569 |
| Total People Sold |
3 |
8 |
10 |
15 |
| Total Sell Transactions |
3 |
8 |
14 |
25 |
| End Date |
2013-03-21 |
2012-12-18 |
2012-06-19 |
2011-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hantson Ludwig |
Corporate Vice President |
• – – |
2013-06-03 |
4 |
D |
$70.44 |
$245,906 |
D/D |
(3,491) |
84,311 |
|
- |
|
| Devitt Blake E |
Director |
– • – |
2013-05-22 |
4 |
S |
$72.34 |
$72,340 |
D/D |
(1,000) |
20,613 |
|
2% |
|
| Bufalino Sebastian J |
Corporate Vice President |
• – – |
2013-05-20 |
4 |
AS |
$73.75 |
$1,770,000 |
D/D |
(24,000) |
5,599 |
|
-3% |
|
| Bufalino Sebastian J |
Corporate Vice President |
• – – |
2013-05-20 |
4 |
OE |
$34.85 |
$836,400 |
D/D |
24,000 |
29,599 |
|
- |
|
| Davis Robert M |
Corporate Vice President |
• – – |
2013-05-17 |
4 |
OE |
$51.21 |
$6,925,428 |
D/D |
133,800 |
251,242 |
|
- |
|
| Davis Robert M |
Corporate Vice President |
• – – |
2013-05-17 |
4 |
AS |
$73.00 |
$9,548,400 |
D/D |
(130,800) |
120,442 |
|
-3% |
|
| Stallkamp Thomas T |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
4,933 |
|
- |
|
| Forsyth John D |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
19,616 |
|
- |
|
| Gavin James R III |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
21,381 |
|
- |
|
| Chowdhry Uma |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
2,400 |
|
- |
|
| Chen Thomas F |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
2,400 |
|
- |
|
| Storm Kees J |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
15,518 |
|
- |
|
| Storm Kees J |
Director |
– • – |
2013-05-07 |
4 |
D |
$68.58 |
$40,051 |
D/D |
(584) |
14,934 |
|
- |
|
| Hellman Peter S |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
12,835 |
|
- |
|
| Uhrich Carole J |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
7,041 |
|
- |
|
| Devitt Blake E |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
21,613 |
|
- |
|
| Stroucken Albert P L |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
14,068 |
|
- |
|
| Hockmeyer Wayne T |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
9,131 |
|
- |
|
| Fosler Gail D |
Director |
– • – |
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
29,175 |
|
- |
|
| Bufalino Sebastian J |
Corporate Vice President |
• – – |
2013-03-06 |
4 |
D |
$69.97 |
$9,166 |
D/D |
(131) |
5,563 |
|
- |
|
| Parkinson Robert L Jr |
Chairman of the Board & CEO |
• • – |
2013-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
464,518 |
|
- |
|
| Bufalino Sebastian J |
Corporate Vice President |
• – – |
2013-03-04 |
4 |
D |
$69.18 |
$9,685 |
D/D |
(140) |
5,662 |
|
- |
|
| Bufalino Sebastian J |
Corporate Vice PresidentOffice |
• – – |
2013-03-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
3,334 |
|
- |
|
| Bufalino Sebastian J |
Corporate Vice President |
• – – |
2013-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
5,802 |
|
- |
|
| Batchelor Phillip L. |
Corporate Vice President |
• – – |
2013-03-01 |
4 |
D |
$68.90 |
$59,943 |
D/D |
(870) |
16,825 |
|
- |
|
534 Records found
|
|
Page 1 of 22 |
|
|
0.15 (0.21%) 
